Meme Kanseri Olgularının Retrospektif Değerlendirilmesi

Tuba Devrim; Merva Aydemir Akkaya; Pınar Atasoy; Mahi Balcı; Canan Altunkaya; Mehmet Zengin

Research Article

Meme Kanseri Olgularının Retrospektif Değerlendirilmesi

Year 2020, Volume: 10 Issue: 1, 51 - 55, 01.04.2020

Tuba Devrim Merva Aydemir Akkaya Pınar Atasoy Mahi Balcı Canan Altunkaya Mehmet Zengin

Abstract

Amaç: Bu çalışma ile meme kanseri tanısı almış kadınlarda klinikopatolojik parametrelerin retrospektif olarak değerlendirilmesi ve moleküler alt tiplerin araştırılması amaçlandı. Materyal ve Metot: Çalışmamız kapsamında Kırıkkale Üniversitesi Tıp Fakültesi Tıbbi Patoloji Anabilim Dalı arşivi taranarak Ocak 2007-Haziran 2019 tarihleri arasında meme kanseri tanısı verilmiş 191 hasta incelendi. Bulgular: İncelenen histopatolojik tümör tipleri, meme tümörlerinin Dünya Sağlık Örgütü 2012 sınıflamasına göre, en yüksek oranda (%89) özel tip olmayan (NST, duktal) meme kanseri olgularına ait olduğu belirlendi. Tümör çapı bakımından en büyük grubu (%48,7) 2–5 cm arası olan olguların oluşturduğu anlaşıldı. Modifiye ScarffBloom-Richardson ile değerlendirilen meme kanseri derece 2 (%55,5) tümörler, alışmamızdaki en büyük grubu oluşturdu. Yaş grubu arttıkça tümör derecesinin arttığı istatistiksel olarak anlamlı düzeyde (p<0,001) belirlendi. Tümörlerde, hormon reseptörleri (ER ve PgR) ile yüksek oranda boyanma saptandı. Hastaların %61,2’sinde lenf nodu invazyonu belirlendi. Bölgesel lenf nodu evresi (pN) 0 olan hastalar %38,8 ile en büyük grubu oluşturdu. Moleküler alt tip bakımından ise en çok (%48,2) luminal A (LA) tipi izlendi. Bunu luminal B (LB) (%37,4), HER2 overeksprese (HO) (%10,8) ve triple negatif (TN) (%4,6) oranları takip etti. LB’nin, LA’ya göre histolojik tümör derecesi bakımından daha ileri olduğu (p<0,001) anlaşıldı. Tümör derecesi HO ve TN’de LA’ya göre daha ileri (p<0,005) düzeyde saptandı. Tümör çapı bakımından ise HO, LA’ya göre yüksek düzeyde tespit (p<0,05) edildi. TN’de HO’ya göre daha büyük bir yaş düzeyi (p<0,05) saptandı. Sonuç: Heterojen bir tümör olan meme kanserinde, tümör derecesi en önemli prognostik faktörlerden biridir. Çalışma verilerimiz bir arada değerlendirildiğinde, meme kanseri moleküler alt tiplerinin belirlenmesinin rutin histopatolojik analiz için önemli yararlar sağlayacağı kanısına varılmıştır

Keywords

meme kanseri; östrojen reseptörü; progesteron reseptörü; HER2, moleküler alt tip

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int JCancer 2015;136:359–86.
2. Network, CGA. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61–70.
3. Ma C, Nepal M, Kim JH, Fan P, Fei P. A new look at molecular biology of breast cancer. Cancer Biol Ther 2019;20(1):1–5.
4. Pérez-Rodríguez G. Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social. Cir 2015;83(3):193–8.
5. Cavalli LR, Cavalli IJ. Molecular classification and prognostic signatures of breast tumors. In: Urban C, Rietjens M, El-Tamer M, Sacchini V (eds) Oncoplastic and reconstructive breast surgery. Springer, Cham; 2019, pp.129–138.
6. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24(2):S26-S35.
7. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathology 2010;23:S60-S64.
8. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011;3;121(10):3786–3788.
9. Alcalá-Corona SA, Anda-Jáuregui G, Espinal-Enríquez J, Hernández-Lemus E. Network modularity in breast cancer molecular subtypes. Front Physiol 2017;8:915.
10. Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: A 2015 update. Arch Pathol Lab Med 2016;140(8):806–14.
11. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012;131(3):1061–6.
12. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast, 4th ed. Lyon, IARC Press; 2012, pp.143–7.
13. Viale G. The current state of breast cancer classification. Annals of Oncology 2012;23(10):x207-x210.
14. Abubakar M, Figueroa J, Ali HR, Blows F, Lissowska J, Caldas C, Easton DF, et al. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Modern Pathology 2019; Apr 11.
15. Tekin L, Doğan E. Meme kanserlerinin alt tiplerine göre patolojik özelliklerinin değerlendirilmesi. FÜ Sağ Bil Tıp Derg 2018;32(3):129–132.
16. Kondov B, Milenkovikj Z, Kondov G, Petrushevska G, Basheska N, Bogdanovska-Todorovska M, et al. Presentation of the molecular subtypes of breast cancer detected by ımmunohistochemistry in surgically treated patients. Maced J Med Sci 2018 6;6(6), 961–967.
17. Ünçel M, Aköz G, Yıldırım Z, Pişkin G, Değirmenci M, Solakoğlu et al. Meme kanserinin klinikopatolojik özelliklerinin moleküler alt tipe göre değerlendirilmesi. Tepecik Eğit Araşt Hast Derg 2015;25(3):151–156.
18. Landry AP, Zador Z, Haq R, Cusimano MD. Reclassification of breast cancer: towards improved diagnosis and outcome. PLoS One 2019;22;14(5): e0217036.
19. Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E. Meme karsinomunda moleküler sınıflama: gelenekselden yeni döneme yolculuk. J Breast Health 2015;11:59–66.
20. Waks AG, Winer EP. Breast Cancer Treatment, A Review. JAMA 2019;321(3):288–300.
21. Giraldo NA, Peske JD, Sautès-Fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Archiv 2019;474(4):463–474.
22. Fallahpour S, Navaneelan T, De P, Borgo A. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open 2017;5(3): E734-E739.
23. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer 2010;10(4):294–300.
24. Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal AfricanAmerican women: age-specific prevalence and survival. J Surg Res 2007;143(1):109–18.
25. Parise CA, Caggiano V. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2− breast cancer subtypes. Cancer Causes Control 2019, 30, 5, 417–424.
26. Prado-Vázquez G, Gámez-Pozo A, Trilla-Fuertes L, Arevalillo JM, Zapater-Moros A, Ferrer-Gómez M, et al. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. Scientific Reports 2019;9, 1538.
27. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: ımproving patient selection for treatment. Cancer Discov 2019;9(2):176–198.
28. Munoz DF, Plevritis SK. Estimating breast cancer survival by molecular subtype in the absence of screening and adjuvant treatment. Med Decis Making 2018;38(1):32S-43S.

Year 2020, Volume: 10 Issue: 1, 51 - 55, 01.04.2020

Tuba Devrim Merva Aydemir Akkaya Pınar Atasoy Mahi Balcı Canan Altunkaya Mehmet Zengin

Abstract

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int JCancer 2015;136:359–86.
2. Network, CGA. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61–70.
3. Ma C, Nepal M, Kim JH, Fan P, Fei P. A new look at molecular biology of breast cancer. Cancer Biol Ther 2019;20(1):1–5.
4. Pérez-Rodríguez G. Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social. Cir 2015;83(3):193–8.
5. Cavalli LR, Cavalli IJ. Molecular classification and prognostic signatures of breast tumors. In: Urban C, Rietjens M, El-Tamer M, Sacchini V (eds) Oncoplastic and reconstructive breast surgery. Springer, Cham; 2019, pp.129–138.
6. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24(2):S26-S35.
7. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern Pathology 2010;23:S60-S64.
8. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011;3;121(10):3786–3788.
9. Alcalá-Corona SA, Anda-Jáuregui G, Espinal-Enríquez J, Hernández-Lemus E. Network modularity in breast cancer molecular subtypes. Front Physiol 2017;8:915.
10. Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: A 2015 update. Arch Pathol Lab Med 2016;140(8):806–14.
11. Collins LC, Marotti JD, Gelber S, Cole K, Ruddy K, Kereakoglow S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012;131(3):1061–6.
12. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. WHO Classification of Tumours of the Breast, 4th ed. Lyon, IARC Press; 2012, pp.143–7.
13. Viale G. The current state of breast cancer classification. Annals of Oncology 2012;23(10):x207-x210.
14. Abubakar M, Figueroa J, Ali HR, Blows F, Lissowska J, Caldas C, Easton DF, et al. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Modern Pathology 2019; Apr 11.
15. Tekin L, Doğan E. Meme kanserlerinin alt tiplerine göre patolojik özelliklerinin değerlendirilmesi. FÜ Sağ Bil Tıp Derg 2018;32(3):129–132.
16. Kondov B, Milenkovikj Z, Kondov G, Petrushevska G, Basheska N, Bogdanovska-Todorovska M, et al. Presentation of the molecular subtypes of breast cancer detected by ımmunohistochemistry in surgically treated patients. Maced J Med Sci 2018 6;6(6), 961–967.
17. Ünçel M, Aköz G, Yıldırım Z, Pişkin G, Değirmenci M, Solakoğlu et al. Meme kanserinin klinikopatolojik özelliklerinin moleküler alt tipe göre değerlendirilmesi. Tepecik Eğit Araşt Hast Derg 2015;25(3):151–156.
18. Landry AP, Zador Z, Haq R, Cusimano MD. Reclassification of breast cancer: towards improved diagnosis and outcome. PLoS One 2019;22;14(5): e0217036.
19. Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E. Meme karsinomunda moleküler sınıflama: gelenekselden yeni döneme yolculuk. J Breast Health 2015;11:59–66.
20. Waks AG, Winer EP. Breast Cancer Treatment, A Review. JAMA 2019;321(3):288–300.
21. Giraldo NA, Peske JD, Sautès-Fridman C, Fridman WH. Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Archiv 2019;474(4):463–474.
22. Fallahpour S, Navaneelan T, De P, Borgo A. Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data. CMAJ Open 2017;5(3): E734-E739.
23. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer 2010;10(4):294–300.
24. Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal AfricanAmerican women: age-specific prevalence and survival. J Surg Res 2007;143(1):109–18.
25. Parise CA, Caggiano V. Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2− breast cancer subtypes. Cancer Causes Control 2019, 30, 5, 417–424.
26. Prado-Vázquez G, Gámez-Pozo A, Trilla-Fuertes L, Arevalillo JM, Zapater-Moros A, Ferrer-Gómez M, et al. A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses. Scientific Reports 2019;9, 1538.
27. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: ımproving patient selection for treatment. Cancer Discov 2019;9(2):176–198.
28. Munoz DF, Plevritis SK. Estimating breast cancer survival by molecular subtype in the absence of screening and adjuvant treatment. Med Decis Making 2018;38(1):32S-43S.

There are 28 citations in total.

Details

Primary Language	Turkish
Subjects	Clinical Sciences
Journal Section	Research Article
Authors	Tuba Devrim This is me Merva Aydemir Akkaya This is me Pınar Atasoy This is me Mahi Balcı This is me Canan Altunkaya This is me Mehmet Zengin This is me
Publication Date	April 1, 2020
Published in Issue	Year 2020 Volume: 10 Issue: 1

Cite

APA	Devrim, T., Aydemir Akkaya, M., Atasoy, P., Balcı, M., et al. (2020). Meme Kanseri Olgularının Retrospektif Değerlendirilmesi. Kafkas Journal of Medical Sciences, 10(1), 51-55.
AMA	Devrim T, Aydemir Akkaya M, Atasoy P, Balcı M, Altunkaya C, Zengin M. Meme Kanseri Olgularının Retrospektif Değerlendirilmesi. KAFKAS TIP BİL DERG. April 2020;10(1):51-55.
Chicago	Devrim, Tuba, Merva Aydemir Akkaya, Pınar Atasoy, Mahi Balcı, Canan Altunkaya, and Mehmet Zengin. “Meme Kanseri Olgularının Retrospektif Değerlendirilmesi”. Kafkas Journal of Medical Sciences 10, no. 1 (April 2020): 51-55.
EndNote	Devrim T, Aydemir Akkaya M, Atasoy P, Balcı M, Altunkaya C, Zengin M (April 1, 2020) Meme Kanseri Olgularının Retrospektif Değerlendirilmesi. Kafkas Journal of Medical Sciences 10 1 51–55.
IEEE	T. Devrim, M. Aydemir Akkaya, P. Atasoy, M. Balcı, C. Altunkaya, and M. Zengin, “Meme Kanseri Olgularının Retrospektif Değerlendirilmesi”, KAFKAS TIP BİL DERG, vol. 10, no. 1, pp. 51–55, 2020.
ISNAD	Devrim, Tuba et al. “Meme Kanseri Olgularının Retrospektif Değerlendirilmesi”. Kafkas Journal of Medical Sciences 10/1 (April 2020), 51-55.
JAMA	Devrim T, Aydemir Akkaya M, Atasoy P, Balcı M, Altunkaya C, Zengin M. Meme Kanseri Olgularının Retrospektif Değerlendirilmesi. KAFKAS TIP BİL DERG. 2020;10:51–55.
MLA	Devrim, Tuba et al. “Meme Kanseri Olgularının Retrospektif Değerlendirilmesi”. Kafkas Journal of Medical Sciences, vol. 10, no. 1, 2020, pp. 51-55.
Vancouver	Devrim T, Aydemir Akkaya M, Atasoy P, Balcı M, Altunkaya C, Zengin M. Meme Kanseri Olgularının Retrospektif Değerlendirilmesi. KAFKAS TIP BİL DERG. 2020;10(1):51-5.

Download Cover Image

Article Files

Full Text